

Remarks

Claims 1-37 are pending in this application. Claims 3-4, 6, 8, 21, and 35 are cancelled. Accordingly, claims 1-2, 5, 7, 9-20, 22-24, 30-34, and 36-37 are now pending in this application.

Applicants note that non-elected subject matter has been deleted from the claims.

Rejections under 35 USC § 112 – First Paragraph

The Office Action asserts that claims 3 and 4 are rejected under 35 U.S.C. 112, 1st paragraph as failing to comply with the enablement requirement of Section 112. Claims 3 and 4 are cancelled herein. Accordingly, Applicants, believe that the rejection is moot and respectfully request its withdrawal.

Rejection under 35 USC § 112 – First Paragraph


The Office Action asserts that claims 1-37 are rejected under 35 U.S.C. 112, 1st paragraph as failing to comply with the enablement requirement of Section 112 in that the term “solvates” is not enabled. The term “solvates” has been deleted from the claims. Accordingly, Applicants, believe that the rejection is overcome by amendment and respectfully request its withdrawal.

Conclusion

The points and concerns of the Examiner have been addressed in full. Applicants respectfully submit that the instant application is in condition for allowance, which is respectfully requested. Should any issues remain unresolved in this application which would bar issuance, the Examiner is invited to contact the undersigned Attorney at (919) 483-6334 to discuss such issues.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to affect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,



John L. Lemanowicz
Attorney for Applicants
Registration No. 37,380

Date: 25 August, 2008
Glaxo Smith Kline
Five Moore Drive, PO Box 13398
Research Triangle Park, North Carolina 27709
(919) 483-8247